Cargando…

Development of an inventory to assess perceived barriers related to PKU treatment

BACKGROUND: According to studies of phenylketonuria (PKU), the Brazilian population’s metabolic control shows unsatisfactory indexes from childhood. Research on patients’ perceived difficulties or barriers to adherence to treatment can help us to comprehend how these outcomes are associated. The pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Teruya, Katia Irie, Remor, Eduardo, Schwartz, Ida Vanessa Doederlein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195505/
https://www.ncbi.nlm.nih.gov/pubmed/32358708
http://dx.doi.org/10.1186/s41687-020-00194-w
_version_ 1783528549735464960
author Teruya, Katia Irie
Remor, Eduardo
Schwartz, Ida Vanessa Doederlein
author_facet Teruya, Katia Irie
Remor, Eduardo
Schwartz, Ida Vanessa Doederlein
author_sort Teruya, Katia Irie
collection PubMed
description BACKGROUND: According to studies of phenylketonuria (PKU), the Brazilian population’s metabolic control shows unsatisfactory indexes from childhood. Research on patients’ perceived difficulties or barriers to adherence to treatment can help us to comprehend how these outcomes are associated. The present study aimed to: (1) describe the development of an inventory for identifying the most frequent and relevant perceived barriers to PKU treatment from the perspective of patients, caregivers, and healthcare professionals; (2) evaluate certain psychometric characteristics of the new measure; and, (3) explore potential predictors (sociodemographic and medical characteristics) that may contribute to increasing the number of perceived barriers and examine whether the number of barriers is associated with the degree of adherence shown by the patient. RESULTS: Participants in the study were 23 patients with PKU (M age = 18.0 years; SD = 7.3; range 6 to 34 years; 69% early-treated) in classical (n = 11) and mild (n = 12) form, and 11 caregivers. The inventory, developed to ascertain perceived barriers to treatment, was completed by patients (≥ 13 years) and caregivers of patients aged 6 to 17 years. Analyses were conducted to investigate whether barrier inventory scores were associated with adherence to treatment as measured by phenylalanine levels in patients’ medical records. Scores on the inventory differed across the patient age groups: adolescents had lower scores (i.e. reported fewer barriers) compared with those of adults (U = 8.000, p = 0.008); patients with better recent metabolic control also reported fewer perceived barriers than did patients with poor adherence (U = 20.000, p = 0.009); and the number of perceived barriers was positively associated with recent blood phenylalanine concentration (Kendall’s tau(b) = 0.41; p = 0.001). CONCLUSIONS: These results suggest that the inventory has merit in assessing perceived barriers and support the need for further research on barriers perceived by PKU patients.
format Online
Article
Text
id pubmed-7195505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-71955052020-05-05 Development of an inventory to assess perceived barriers related to PKU treatment Teruya, Katia Irie Remor, Eduardo Schwartz, Ida Vanessa Doederlein J Patient Rep Outcomes Research BACKGROUND: According to studies of phenylketonuria (PKU), the Brazilian population’s metabolic control shows unsatisfactory indexes from childhood. Research on patients’ perceived difficulties or barriers to adherence to treatment can help us to comprehend how these outcomes are associated. The present study aimed to: (1) describe the development of an inventory for identifying the most frequent and relevant perceived barriers to PKU treatment from the perspective of patients, caregivers, and healthcare professionals; (2) evaluate certain psychometric characteristics of the new measure; and, (3) explore potential predictors (sociodemographic and medical characteristics) that may contribute to increasing the number of perceived barriers and examine whether the number of barriers is associated with the degree of adherence shown by the patient. RESULTS: Participants in the study were 23 patients with PKU (M age = 18.0 years; SD = 7.3; range 6 to 34 years; 69% early-treated) in classical (n = 11) and mild (n = 12) form, and 11 caregivers. The inventory, developed to ascertain perceived barriers to treatment, was completed by patients (≥ 13 years) and caregivers of patients aged 6 to 17 years. Analyses were conducted to investigate whether barrier inventory scores were associated with adherence to treatment as measured by phenylalanine levels in patients’ medical records. Scores on the inventory differed across the patient age groups: adolescents had lower scores (i.e. reported fewer barriers) compared with those of adults (U = 8.000, p = 0.008); patients with better recent metabolic control also reported fewer perceived barriers than did patients with poor adherence (U = 20.000, p = 0.009); and the number of perceived barriers was positively associated with recent blood phenylalanine concentration (Kendall’s tau(b) = 0.41; p = 0.001). CONCLUSIONS: These results suggest that the inventory has merit in assessing perceived barriers and support the need for further research on barriers perceived by PKU patients. Springer International Publishing 2020-05-01 /pmc/articles/PMC7195505/ /pubmed/32358708 http://dx.doi.org/10.1186/s41687-020-00194-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Teruya, Katia Irie
Remor, Eduardo
Schwartz, Ida Vanessa Doederlein
Development of an inventory to assess perceived barriers related to PKU treatment
title Development of an inventory to assess perceived barriers related to PKU treatment
title_full Development of an inventory to assess perceived barriers related to PKU treatment
title_fullStr Development of an inventory to assess perceived barriers related to PKU treatment
title_full_unstemmed Development of an inventory to assess perceived barriers related to PKU treatment
title_short Development of an inventory to assess perceived barriers related to PKU treatment
title_sort development of an inventory to assess perceived barriers related to pku treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195505/
https://www.ncbi.nlm.nih.gov/pubmed/32358708
http://dx.doi.org/10.1186/s41687-020-00194-w
work_keys_str_mv AT teruyakatiairie developmentofaninventorytoassessperceivedbarriersrelatedtopkutreatment
AT remoreduardo developmentofaninventorytoassessperceivedbarriersrelatedtopkutreatment
AT schwartzidavanessadoederlein developmentofaninventorytoassessperceivedbarriersrelatedtopkutreatment